查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2004723

醫藥及醫療設備組合產品市場：2026-2032年全球市場預測（依產品類型、技術、劑型、治療領域及最終用戶分類）

Drug-Device Combination Products Market by Product Type, Technology, Dosage Form, Therapeutic Class, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，醫藥和醫療設備器材市場總值將達到 1,564.6 億美元，到 2026 年將成長至 1,687 億美元，到 2032 年將達到 2,746.1 億美元，複合年成長率為 8.36%。

主要市場統計數據
基準年 2025 1564.6億美元
預計年份：2026年 1687億美元
預測年份 2032 2746.1億美元
複合年成長率 (%) 8.36%

對聯合療法進行全面概述，將臨床創新、監管細微差別和商業化要求置於現代開發生命週期中。

藥理學與醫療設備工程的整合已發展成為一個重要的學術領域，它處於醫療創新和醫療保健服務的關鍵交匯點。藥物-醫療設備複合物將活性成分與精心設計的遞送系統結合，以增強治療效果、提高用藥依從性並催生新的治療模式。本文概述了科學進步、以使用者為中心的設計以及監管要求相互交織的複雜圖景，這既為製造商、臨床醫生和支付方帶來了機遇，也帶來了挑戰。

技術融合、監管完善以及對醫療保健服務期望的改變，如何重新定義聯合療法的開發方法和商業化策略？

變革性的技術、監管和醫療服務模式正在重塑醫藥和醫療設備的組合格局。智慧型設備功能的提升，例如嵌入式感測器、自動配藥機制和數位化監測，正在催生新的用藥依從性管理和遠端醫療監測模式。這些技術進步正在加速從單一產品模式向整合式醫療生態系統的轉變，在這個生態系統中，設備和軟體透過數據驅動的洞察創造價值。

評估 2025 年貿易和關稅變化對聯合治療籌資策略、製造本地化選擇和供應鏈韌性的下游影響。

2025年推出的關稅政策變化和貿易措施的累積影響正對聯合治療產品相關相關人員的採購、生產和分銷策略產生重大影響。關鍵組件、原料和成品的關稅調整提高了全球價值鏈的成本可見性，迫使企業重新評估籌資策略和與供應商的合約條款。為此，許多企業正在加快多元化發展步伐，尋找替代供應商並實施雙重採購安排，以降低單一來源依賴的風險並維持供應的連續性。

將產品類型、底層技術、劑型、治療領域和最終用戶環境連結起來的綜合細分觀點，指導策略優先排序。

一套精細的市場細分框架揭示了產品、技術、劑型、治療領域和終端用戶群如何影響整個複雜產品市場的策略和創新重點。基於產品類型，此市場研究涵蓋藥物釋放型支架、吸入器、注射系統、預填充式注射器和注射筆、外用藥物以及經皮貼片。注射系統類別進一步細分為自動注射器和無針注射器，二者分別面臨不同的技術和使用者介面挑戰。這種產品層面的差異不僅影響監管路徑、包裝要求和臨床醫生培訓需求，也決定了在不影響藥物穩定性的前提下，數位化功能在設備中的應用程度。

不同地區管理體制、採購實踐和生產重點的差異如何影響聯合療法的開發和商業化策略？

區域趨勢持續對監管預期、生產策略和複雜產品的商業性部署產生重大影響，各主要區域呈現不同的模式。在美洲，法規結構正在趨於統一，其核心是基於風險的評估和上市後監測，而採購機構則優先考慮臨床證據和供應鏈透明度。這種情況正在推動能夠顯著改善用藥依從性和治療效果的解決方案的出現，從而支持將產品部署與培訓和遠端監測等服務相結合的經營模式。

製造商、供應商和服務供應商之間的合作聯盟、對平台的投資以及產能擴張如何重新定義組合產品生態系統中的競爭優勢。

產品開發商、供應商和服務供應商之間的競爭呈現出平台創新、策略夥伴關係和能力建構投資三者融合的趨勢。成熟的製藥公司和醫療設備製造商正日益建立合作關係，將配方專業知識與器材工程相結合，並常常圍繞臨床療效和通用的商業目標來協調獎勵。同時，專注於醫療技術的專業公司和科技Start-Ups則致力於感測器整合、注射裝置小型化或穿戴式黏合系統等細分領域，並透過授權和收購來拓展產品系列。

可操作的跨職能策略和戰術性投資，能夠降低開發風險，加強部署途徑，並保持競爭優勢。

致力於將創新轉化為永續市場成功的產業領導者應制定一套協作且切實可行的策略，協調科學、監管、生產和商業職能。首先，他們應從研發早期階段就引入跨部門管治，使配方要求與器材工程、人體工學和軟體檢驗需求保持一致。這種整合的管治模式能夠減少返工，使監管申報更加清晰，並加快就對支付方和臨床醫生至關重要的臨床終點達成共識。

透過高度透明的混合方法研究途徑，結合專家訪談、有針對性的二手研究和三角檢驗，檢驗了研究結果的有效性，同時也承認了調查方法的局限性。

本分析所依據的研究結合了定性和定量方法，旨在提取可操作的洞見，同時保持方法論的嚴謹性。關鍵資料來源包括與跨學科專家（如臨床醫生、法規專家、採購經理和製造工程師）進行的結構化訪談，這些訪談提供了關於營運限制和市場推廣促進因素的真實觀點。此外，還組織了有針對性的專家小組，以檢驗新出現的主題，並檢驗策略建議在不同產品類型和地區的適用性。

簡潔地總結了整合開發、供應鏈敏捷性和實證商業化是聯合治療成功的核心要求。

總之，藥品和醫療設備的組合在現代醫療保健中佔據著動態且重要的策略地位，具有提高治療效果、病患依從性和系統性療效的潛力。最顯著的變化發生在技術整合、監管調整和不斷演進的醫療服務模式的交會點。為了在這種環境下取得成功，製造商必須採用整合開發模式，投資於供應鏈的柔軟性，並優先產生能夠證明其臨床和經濟價值的證據。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：醫藥及醫療設備組合產品市場：依產品類型分類

  • 藥物釋放型支架
  • 吸入器
  • 注射系統
    • 自動注射器
    • 無針注射器
  • 預填充式注射器和注射筆
  • 外用藥物
  • 經皮吸收貼劑

第9章：醫藥及醫療設備組合產品市場：依技術分類

  • 先進的釋放技術
  • 可生物分解技術
  • 傳統醫療設備與製藥聯合技術
  • 智慧型裝置技術
    • 自動化管理
    • 數位監控

第10章：以劑型分類的藥品和醫療設備複雜產品市場

  • 液體
  • 半固態製劑
    • 奶油
    • 軟膏
    • 粉末
  • 固態劑量
    • 膠囊
    • 藥片

第11章：依治療領域分類的藥品和醫療設備組合產品市場

  • 循環系統藥物
  • 糖尿病/內分泌學
  • 荷爾蒙補充療法
  • 抗癌藥物
    • 化療
    • 參與式癌症治療
  • 疼痛管理

第12章：醫藥及醫療設備組合產品市場：依最終用戶分類

  • 門診手術中心
  • 居家醫療設施
  • 醫院和診所
  • 專科診所

第13章：醫藥及醫療設備組合產品市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：醫藥及醫療設備綜合產品市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：藥品和醫療設備綜合產品市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國藥品和醫療設備綜合產品市場

第17章：中國醫藥醫療設備綜合產品市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • AbbVie Inc.
  • B. Braun SE
  • Baxter International Inc.
  • Becton, Dickinson and Company
  • BIOTRONIK SE & Co. KG
  • Boston Scientific Corporation
  • Braile Biomedica
  • Cardinal Health, Inc.
  • CODAN Companies
  • Cook Group Incorporated
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi
  • ICU Medical, Inc.
  • InSitu Technologies Inc.
  • JMS North America Corporation
  • Lepu Medical Technology Company
  • Medtronic PLC
  • MicroPort Scientific Corporation
  • Novartis AG
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • SOOIL Developments Co., Ltd.
  • Stryker Corporation
  • Teleflex Incorporated
  • Terumo Group
  • Viatris Inc.
  • WL Gore & Associates Inc.
Product Code: MRR-742BD517D8D5

The Drug-Device Combination Products Market was valued at USD 156.46 billion in 2025 and is projected to grow to USD 168.70 billion in 2026, with a CAGR of 8.36%, reaching USD 274.61 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 156.46 billion
Estimated Year [2026] USD 168.70 billion
Forecast Year [2032] USD 274.61 billion
CAGR (%) 8.36%

A comprehensive orientation to combination therapeutics that situates clinical innovation, regulatory nuance, and commercialization imperatives within a modern development lifecycle

The integration of pharmacology and device engineering has evolved into a defining discipline at the intersection of medical innovation and healthcare delivery. Drug-device combination products bring together active pharmaceutical ingredients and engineered delivery systems to enhance therapeutic performance, improve adherence, and enable new modes of care. This introduction frames a multidimensional landscape in which scientific advances, user-centered design, and regulatory expectations converge to create both opportunity and complexity for manufacturers, clinicians, and payers.

Recent years have seen a shift from incremental enhancements toward systems-level solutions that embed sensors, connectivity, and data analytics into delivery platforms. Consequently, development teams must orchestrate expertise spanning formulation science, materials engineering, software development, human factors, and quality systems. At the same time, regulatory pathways have adapted to account for hybrid product characteristics, emphasizing demonstration of safety and efficacy across both device and drug components, as well as post-market surveillance strategies tailored to combination-specific risks.

From a commercialization perspective, payers and procurement channels are increasingly focused on real-world performance and total cost of care implications, which can accelerate adoption where clinical and economic value are clearly demonstrated. Manufacturers therefore find that early alignment between clinical development, regulatory strategy, and market access planning is essential. This introduction sets the stage for a deeper analysis of transformative shifts, tariff-driven supply chain impacts, segmentation nuances, regional dynamics, and actionable steps leaders can take to succeed in this rapidly evolving domain.

How converging technology, regulatory refinement, and shifting care delivery expectations are redefining development approaches and commercialization strategies in combination therapeutics

The landscape for drug-device combination products is being reshaped by a confluence of technological, regulatory, and care-delivery forces that together are driving transformative change. Advances in smart device capabilities-such as embedded sensors, automatic dosing mechanisms, and digital monitoring-are enabling new models of adherence management and remote therapeutic monitoring. These technological enhancements are fostering a move from discrete product offerings toward integrated care ecosystems in which devices and software generate value through data-driven insights.

Regulatory authorities are responding by refining guidance that addresses hybrid product evaluation, cybersecurity expectations, and post-market data collection, thereby elevating the bar for integrated validation and lifecycle management. Concurrently, manufacturers are pursuing modular design philosophies and platform approaches to accelerate iteration while managing regulatory complexity. Supply chain resilience and manufacturing flexibility have become strategic priorities, prompting investments in nearshoring, multi-sourcing, and process automation to minimize disruption and protect time-to-market.

Clinician and patient expectations are also evolving: user-centric design, simplified administration, and demonstrable improvements in patient outcomes are central to adoption. Payers increasingly demand evidence of cost-effectiveness and real-world utility, which incentivizes manufacturers to incorporate health economics and outcomes research earlier in development. As a result, the most successful organizations are those that align R&D, regulatory, commercial, and manufacturing functions around a shared, data-informed value proposition that supports scalable, sustainable deployment of combination therapies.

Evaluating the downstream consequences of 2025 trade and tariff shifts on sourcing strategies, manufacturing localization choices, and supply chain resilience for combination therapies

The cumulative impact of tariff policy changes and trade measures introduced in 2025 has had meaningful implications for the procurement, manufacturing, and distribution strategies of combination product stakeholders. Tariff adjustments on critical components, raw materials, and finished goods have heightened cost visibility across global value chains, prompting companies to reassess sourcing strategies and contractual terms with suppliers. In response, many organizations accelerated diversification efforts, identifying alternate suppliers and dual-sourcing arrangements to mitigate single-origin exposure and maintain continuity of supply.

Beyond direct input costs, tariffs have influenced decisions around geographic placement of critical manufacturing activities and investment in localized assembly or final-stage manufacturing. These shifts are often accompanied by careful analysis of regulatory compliance across jurisdictions, given that relocating production can entail new registration, inspection, and quality system obligations. Firms have therefore balanced the cost impact of tariffs against the regulatory complexity and lead time associated with establishing compliant manufacturing in new regions.

Importantly, tariff-driven pressures have incentivized tighter collaboration across procurement, regulatory, and product teams to ensure that adjustments in sourcing do not compromise material compatibility, device performance, or drug stability. Industry response has included renegotiated supplier agreements with built-in contingency clauses, expanded use of contractual hedging strategies, and targeted investments in supply chain visibility technologies. Taken together, these responses reflect a pragmatic effort to preserve product integrity and market access while adapting to an altered trade environment.

An integrated segmentation perspective connecting product types, enabling technologies, dosage forms, therapeutic classes, and end-user environments to guide strategic prioritization

A nuanced segmentation framework illuminates how product, technology, dosage form, therapeutic focus, and end-user context shape strategy and innovation priorities across the combination product landscape. Based on Product Type, the market is studied across Drug-Eluting Stents, Inhalers, Injector Systems, Prefilled Syringes & Pens, Topical Medicines, and Transdermal Patches; the Injector Systems category is further examined across Auto-Injectors and Needle-Free Injectors, each presenting different engineering and user-interface challenges. This product-level differentiation influences regulatory pathways, packaging requirements, and clinician training needs, and it also determines the extent to which devices can incorporate digital features without disrupting drug stability.

Based on Technology, the market is studied across Advanced Release Technologies, Biodegradable Technology, Conventional Device-Drug Technology, and Smart Device Technologies; the Smart Device Technologies subgroup is further analyzed for Automatic Dosing and Digital Monitoring capabilities. Adoption of advanced release and biodegradable platforms often hinges on material science innovations and compatibility testing, while smart technologies demand robust software verification, cybersecurity measures, and data interoperability strategies to support clinical workflows and reimbursement claims.

Based on Dosage Form, the market is studied across Liquid Dosage Forms, Semi-Solid Dosage Forms, and Solid Dosage Forms; the Semi-Solid Dosage Forms are further explored through Creams, Ointments, and Powders, and the Solid Dosage Forms are further considered across Capsules and Tablets. Dosage form selection affects stability, device design, and patient administration protocols, and it imposes specific analytical and quality control requirements. Based on Therapeutic Class, the market is studied across Cardiovascular Medications, Diabetes & Endocrinology, Hormonal Replacement Therapy, Oncology Drugs, and Pain Management; the Oncology Drugs subset is further categorized into Chemotherapy and Participatory Oncology Treatment, reflecting divergent safety profiles and monitoring needs. Finally, Based on End-User, the market is studied across Ambulatory Surgical Centers, Homecare Settings, Hospitals and Clinics, and Specialty Clinics, which together define differing operational constraints, training resources, and procurement models. Integrating these segmentation dimensions helps stakeholders prioritize product design trade-offs, regulatory strategy, and market access efforts according to the technical, clinical, and delivery-context nuances that matter most.

How divergent regulatory regimes, procurement behaviors, and manufacturing priorities across major regions shape development and commercialization strategies for combination therapeutics

Regional dynamics continue to exert strong influence over regulatory expectations, manufacturing strategies, and commercial deployment of combination products, with distinct patterns emerging across major geographies. In the Americas, regulatory frameworks are increasingly harmonized around risk-based evaluation and post-market surveillance expectations, while purchaser institutions emphasize clinical evidence and supply chain visibility. These conditions favor solutions that demonstrate measurable improvements in adherence and outcomes, and they support commercial models that pair product deployment with services such as training and remote monitoring.

Across Europe, Middle East & Africa, diverse regulatory regimes and procurement modalities require adaptive market access strategies that account for national reimbursement mechanisms and localized clinical guidelines. In this complex environment, manufacturers often prioritize region-specific regulatory expertise and targeted pilot programs to establish clinical value and payer acceptance. Moreover, the emphasis on sustainability and circular economy principles in parts of this region can influence material selection and end-of-life planning for device components.

The Asia-Pacific region presents a combination of rapid adoption potential and heterogeneity in regulatory maturity. Several markets in this region are expediting approvals for innovative delivery platforms while simultaneously building local manufacturing capability. These dynamics make Asia-Pacific attractive for companies seeking scale and cost efficiencies, but they also demand careful navigation of intellectual property protection, localization requirements, and partnership models with local distributors and contract manufacturers. Taken together, regional insights underscore the importance of tailoring regulatory, manufacturing, and commercial strategies to local realities while maintaining global standards for quality and evidence generation.

How collaborative alliances, platform investments, and capability expansion among manufacturers, suppliers, and service providers are redefining competitive advantage in combination product ecosystems

Competitive behavior among product developers, suppliers, and service providers is characterized by a blend of platform innovation, strategic partnerships, and capability-building investments. Established pharmaceutical firms and device manufacturers are increasingly entering into collaborative arrangements to combine formulation expertise with device engineering, often structuring alliances to align incentives around clinical outcomes and shared commercial goals. At the same time, specialized medtech companies and technology startups focus on niche capabilities-such as sensor integration, injection mechanism miniaturization, or wearable adhesion systems-that can be licensed or acquired to complete broader product portfolios.

Supply chain and manufacturing players are differentiating through investments in scalable, compliant assembly capabilities and quality management systems tailored for combination products. Contract development and manufacturing organizations are expanding service offerings to include integrated testing, stability programs, and human factors engineering support to reduce time-to-market for sponsors. Additionally, software vendors and digital health specialists are forging relationships with device and drug developers to provide data platforms, analytics, and interoperability solutions that support remote monitoring and adherence programs.

Regulatory consultants and clinical research organizations are also adapting, offering end-to-end support for regulatory strategy, clinical validation, and post-market evidence generation specific to hybrid product requirements. Across this ecosystem, successful companies demonstrate a capacity to manage complex multidisciplinary programs, deploy capital selectively to bridge capability gaps, and structure commercial models that highlight demonstrable improvements in patient outcomes and system-level efficiencies.

Practical cross-functional strategies and tactical investments that enable organizations to reduce development risk, strengthen adoption pathways, and sustain competitive differentiation

Industry leaders seeking to translate innovation into sustained market success should pursue a set of coordinated, actionable strategies that align scientific, regulatory, manufacturing, and commercial functions. First, embed cross-functional governance early in development to reconcile formulation requirements with device engineering, human factors, and software validation needs. This integrated governance model reduces rework, enables clearer regulatory submissions, and accelerates alignment on clinical endpoints that matter to payers and clinicians.

Second, prioritize supply chain resilience by diversifying critical component sourcing and investing in visibility tools that track provenance and quality attributes. Where feasible, evaluate nearshoring or flexible manufacturing arrangements for final assembly to shorten lead times and simplify regulatory logistics. Third, incorporate digital features and data strategies that augment therapeutic value while ensuring robust cybersecurity, privacy compliance, and interoperability with existing clinical systems. Early engagement with regulators on digital elements can clarify expectations and reduce downstream uncertainty.

Fourth, adopt value-based evidence generation approaches that combine clinical trials with pragmatic, real-world outcome studies to demonstrate both clinical efficacy and economic impact. Align commercial models accordingly, offering bundled solutions that pair product access with training, support services, and data-driven programs to improve adherence. Finally, cultivate strategic partnerships and targeted M&A to fill capability gaps rather than trying to internalize every technical domain. By focusing on these priorities, leaders can reduce development risk, enhance adoption, and create defensible value propositions in an increasingly integrated therapeutic environment.

A transparent mixed-methods research approach combining expert interviews, targeted secondary analysis, and triangulation to validate insights while acknowledging methodological limitations

The research behind this analysis combines qualitative and quantitative methods designed to surface actionable insights while maintaining methodological rigor. Primary inputs included structured interviews with cross-disciplinary subject-matter experts, including clinical practitioners, regulatory specialists, procurement leaders, and manufacturing engineers, which provided real-world perspectives on operational constraints and adoption drivers. These interviews were supplemented by targeted expert panels to validate emergent themes and test the applicability of strategic recommendations across different product types and regions.

Secondary research drew on peer-reviewed literature, regulatory guidance documents, standards publications, and company disclosures to build a factual baseline around technical capabilities, safety considerations, and policy trends. Data triangulation techniques were applied to reconcile differing viewpoints and to ensure that conclusions reflect convergent evidence rather than isolated observations. Where appropriate, case studies of recent product launches and regulatory decisions were analyzed to extract lessons on go-to-market sequencing, evidence generation, and post-market surveillance.

Quality assurance procedures included independent review by methodological peers, consistency checks across data sources, and sensitivity analysis to identify areas of uncertainty. Limitations of the approach are acknowledged, particularly regarding rapidly evolving technology domains and jurisdiction-specific regulatory actions that may change after the analysis period. To mitigate these limitations, readers are encouraged to supplement the findings with contemporaneous regulatory updates and localized expert input when applying the recommendations to specific program decisions.

A succinct synthesis emphasizing integrated development, supply chain agility, and evidence-based commercialization as the core imperatives for combination therapy success

In conclusion, drug-device combination products occupy a dynamic and strategically important space in modern healthcare, offering the potential to improve therapeutic efficacy, patient adherence, and system-level outcomes. The most consequential shifts are occurring at the intersection of technology integration, regulatory adaptation, and changing care-delivery norms. Success in this environment requires manufacturers to adopt integrated development models, to invest in supply chain flexibility, and to prioritize evidence generation that demonstrates both clinical and economic value.

Stakeholders must also navigate the operational realities introduced by recent trade measures and evolving regional requirements, aligning sourcing and manufacturing choices with regulatory readiness and commercial objectives. Market participants who proactively design for regulatory compliance, user-centered deployment, and robust post-market data collection will be better positioned to secure adoption among clinicians and payers. Collaboration across the ecosystem-linking specialized technology providers, contract manufacturers, clinical networks, and reimbursement experts-remains a central enabler for accelerating innovation while managing risk.

Ultimately, informed decision-making grounded in multidisciplinary evidence and adaptive strategy will determine which organizations translate scientific advances into widely adopted combination therapies. The themes explored in this summary point to a pragmatic path forward: integrate capabilities early, validate value rigorously, and structure commercial models that deliver measurable benefits to patients and healthcare systems alike.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Drug-Device Combination Products Market, by Product Type

  • 8.1. Drug-Eluting Stents
  • 8.2. Inhalers
  • 8.3. Injector Systems
    • 8.3.1. Auto-Injectors
    • 8.3.2. Needle-Free Injectors
  • 8.4. Prefilled Syringes & Pens
  • 8.5. Topical Medicines
  • 8.6. Transdermal Patches

9. Drug-Device Combination Products Market, by Technology

  • 9.1. Advanced Release Technologies
  • 9.2. Biodegradable Technology
  • 9.3. Conventional Device-Drug Technology
  • 9.4. Smart Device Technologies
    • 9.4.1. Automatic Dosing
    • 9.4.2. Digital Monitoring

10. Drug-Device Combination Products Market, by Dosage Form

  • 10.1. Liquid Dosage Forms
  • 10.2. Semi-Solid Dosage Forms
    • 10.2.1. Creams
    • 10.2.2. Ointments
    • 10.2.3. Powders
  • 10.3. Solid Dosage Forms
    • 10.3.1. Capsules
    • 10.3.2. Tablets

11. Drug-Device Combination Products Market, by Therapeutic Class

  • 11.1. Cardiovascular Medications
  • 11.2. Diabetes & Endocrinology
  • 11.3. Hormonal Replacement Therapy
  • 11.4. Oncology Drugs
    • 11.4.1. Chemotherapy
    • 11.4.2. Participatory Oncology Treatment
  • 11.5. Pain Management

12. Drug-Device Combination Products Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Homecare Settings
  • 12.3. Hospitals and Clinics
  • 12.4. Specialty Clinics

13. Drug-Device Combination Products Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Drug-Device Combination Products Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Drug-Device Combination Products Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Drug-Device Combination Products Market

17. China Drug-Device Combination Products Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. AbbVie Inc.
  • 18.7. B. Braun SE
  • 18.8. Baxter International Inc.
  • 18.9. Becton, Dickinson and Company
  • 18.10. BIOTRONIK SE & Co. KG
  • 18.11. Boston Scientific Corporation
  • 18.12. Braile Biomedica
  • 18.13. Cardinal Health, Inc.
  • 18.14. CODAN Companies
  • 18.15. Cook Group Incorporated
  • 18.16. F. Hoffmann-La Roche Ltd.
  • 18.17. Fresenius Kabi
  • 18.18. ICU Medical, Inc.
  • 18.19. InSitu Technologies Inc.
  • 18.20. JMS North America Corporation
  • 18.21. Lepu Medical Technology Company
  • 18.22. Medtronic PLC
  • 18.23. MicroPort Scientific Corporation
  • 18.24. Novartis AG
  • 18.25. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 18.26. SOOIL Developments Co., Ltd.
  • 18.27. Stryker Corporation
  • 18.28. Teleflex Incorporated
  • 18.29. Terumo Group
  • 18.30. Viatris Inc.
  • 18.31. W. L. Gore & Associates Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DRUG-ELUTING STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INHALERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTO-INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY NEEDLE-FREE INJECTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PREFILLED SYRINGES & PENS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TOPICAL MEDICINES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TRANSDERMAL PATCHES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ADVANCED RELEASE TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY BIODEGRADABLE TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CONVENTIONAL DEVICE-DRUG TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AUTOMATIC DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIGITAL MONITORING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CREAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY OINTMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY POWDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CARDIOVASCULAR MEDICATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DIABETES & ENDOCRINOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HORMONAL REPLACEMENT THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PARTICIPATORY ONCOLOGY TREATMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PAIN MANAGEMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOMECARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY HOSPITALS AND CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 212. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 215. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 217. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 218. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 220. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 222. GCC DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 245. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 246. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 249. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 250. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 251. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 252. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 253. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 256. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 257. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 261. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 262. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 263. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 264. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 265. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 267. GLOBAL DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 274. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 275. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 276. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY ONCOLOGY DRUGS, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY INJECTOR SYSTEMS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SMART DEVICE TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY DOSAGE FORM, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 286. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY SOLID DOSAGE FORMS, 2018-2032 (USD MILLION)
  • TABLE 287. CHINA DRUG-DEVICE COMBINATION PRODUCTS MARKET SIZE, BY THERAPEUTIC C